Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Link
https://link.springer.com/content/pdf/10.1007/s00415-022-11507-y.pdf
Reference149 articles.
1. Loeffler T, Schilcher I, Flunkert S, Hutter-Paier B (2020) Neurofilament-light chain as biomarker of neurodegenerative and rare diseases with high translational value. Front Neurosci 14:579
2. Sen MK, Almuslehi MSM, Shortland PJ, Coorssen JR, Mahns DA (2020) Revisiting the pathoetiology of multiple sclerosis: has the tail been wagging the mouse? Front Immunol 11:572186
3. Varhaug KN, Torkildsen Ø, Myhr KM, Vedeler CA (2019) Neurofilament light chain as a biomarker in multiple sclerosis. Front Neurol 10:338
4. Tallantyre EC, Bø L, Al-Rawashdeh O, Owens T, Polman CH, Lowe J, Evangelou N (2009) Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain 132(Pt 5):1190–1199
5. Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K (2018) Axonal loss in the multiple sclerosis spinal cord revisited. Brain Pathol 28(3):334–348
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions;Multiple Sclerosis and Related Disorders;2024-08
2. Real-World Study of Serum Neurofilament Light Chain Levels in Ocrelizumab-Treated People with Relapsing Multiple Sclerosis;Journal of Personalized Medicine;2024-06-27
3. Insights into spinal muscular atrophy from molecular biomarkers;Neural Regeneration Research;2024-06-26
4. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study;European Neurology;2024-06-18
5. Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis;Frontiers in Public Health;2024-04-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3